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ABSTRACT 16 
The kinetoplastid parasite Trypanosoma brucei causes African trypanosomiasis in both 17 
humans and animals. Infections place a significant health and economic burden on 18 
developing nations in sub-Saharan Africa, but few effective anti-parasitic treatments are 19 
currently available. Hence, there is an urgent need to identify new leads for drug 20 
development. The T. brucei neutral sphingomyelinase (TbnSMase) was previously 21 
established as essential to parasite survival, consequently being identified as a potential drug 22 
target. This enzyme may catalyse the single route to sphingolipid catabolism outside the  23 
T. brucei lysosome. To obtain new insight into parasite sphingolipid catabolism, the substrate 24 
specificity of TbnSMase was investigated using electrospray ionization tandem mass 25 
spectrometry (ESI-MS/MS). TbnSMase was shown to degrade sphingomyelin,  26 
inositol-phosphoceramide and ethanolamine-phosphoceramide sphingolipid substrates, 27 
consistent with the sphingolipid complement of the parasites. TbnSMase also catabolised 28 
ceramide-1-phosphate, but was inactive towards sphingosine-1-phosphate. The broad-range 29 
specificity of this enzyme towards sphingolipid species is a unique feature of TbnSMase. 30 
Additionally, ESI-MS/MS analysis revealed previously uncharacterised activity towards  31 
lyso-phosphatidylcholine (lyso-PC), despite the enzyme’s inability to degrade PC. 32 
Collectively, these data underline the enzyme’s importance in choline homeostasis and the 33 
turnover of sphingolipids in T. brucei. 34 
KEYWORDS: lipid catabolism, sphingolipid, choline, lipid extraction, mass spectrometry, 35 
enzyme, activity assay 36 
  37 
Page 2 of 38
Cambridge University Press
Parasitology
For Peer Review
3 
 
KEY FINDINGS 38 
• TbnSMase has broad substrate specificity towards various sphingolipids 39 
• TbnSMase is the first T. brucei enzyme shown to catabolise lyso-phosphatidylcholine 40 
• Sphingosine-1-phosphate, glycosphingolipids and phosphatidylcholine are not 41 
TbnSMase substrates 42 
• TbnSMase plays a direct role in choline homeostasis in bloodstream form parasites 43 
INTRODUCTION 44 
The kinetoplastid parasite Trypanosoma brucei causes African trypanosomiasis in both 45 
humans and animals. Human African trypanosomiasis (HAT) is considered fatal if left 46 
untreated, and poses a serious health risk to an estimated 65 million people in Sub-Saharan 47 
Africa (World Health Organization, 2017a). Recent efforts have led to a dramatic decrease in 48 
reported disease cases, with 2804 cases reported in 2015, although the World Health 49 
Organization estimates the actual number of cases to be 10-fold greater (World Health 50 
Organization, 2017a; b). Research has also produced promising new drug candidates, 51 
however, the risk of parasite resistance and consequent HAT re-emergence still threaten the 52 
progress made in combatting the disease. Animal trypanosomiasis remains a significant 53 
burden, with billions of US dollars lost through livestock infections each year  and few 54 
treatment candidates on the horizon (Shaw et al., 2014). Thus, there is an urgent need to 55 
identify leads for drug development. 56 
T. brucei sphingolipid biosynthesis has long been identified as a potential drug target. Most 57 
eukaryotes are capable of synthesising their own sphingolipids via the de novo biosynthesis 58 
pathway (Fig. 1A), which is highly conserved amongst eukaryotic organisms (Kolter and 59 
Sandhoff, 1999). Although homologues of most of the enzymes involved in this biosynthetic 60 
pathway have been (putatively) identified in T. brucei, many still require biochemical 61 
characterisation (Smith and Bütikofer, 2010). The first reaction in the pathway, condensation 62 
of serine and palmitoyl-CoA, is catalysed by the enzyme serine-palmitoyltransferase (SPT) 63 
(Tidhar and Futerman, 2013). A homologue of this enzyme has been identified in T. brucei, 64 
which was shown to be essential for cell cycle progression and parasite survival (Fridberg et 65 
al., 2008). Inhibiting the initial SPT-catalysed reaction of the T. brucei de novo biosynthesis 66 
pathway disrupted procyclic cytokinesis and kinetoplast segregation, validating the pathway 67 
as a drug target (Fridberg et al., 2008; Smith and Bütikofer, 2010). Although SPT is known to 68 
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be essential in other parasites, such as Plasmodium falciparum (Gerold and Schwarz, 2001), 69 
these findings contrast with research involving the related kinetoplastid parasite Leishmania 70 
major (Denny et al., 2004; Zhang et al., 2007). Unusually, T. brucei has four tandemly linked 71 
genes, each encoding different sphingolipid synthases (TbSLSs1-4) (Sevova et al., 2010). 72 
This family of sphingolipid synthases is orthologous to the S. cerevisiae AUR1-encoded IPC 73 
synthase (Mina et al., 2009), and equivalent enzymes are found in both Leishmania major 74 
(Denny et al., 2006) and Trypanosoma cruzi (De Lederkremer et al., 2011). RNA 75 
interference (RNAi) against the TbSLS1-4 gene locus in bloodstream trypanosomes impeded 76 
growth, ultimately leading to parasite death (Sutterwala et al., 2008). This finding identified 77 
the TbSLSs as potential drug targets. The individual functional specificities of the four 78 
synthases were determined by employing a cell-free synthesis system (Sevova et al., 2010). 79 
TbSLSs 1 and 2 synthesise IPC and EPC respectively (Sevova et al., 2010). TbSLSs 3 and 4 80 
are bi-functional, producing both SM and EPC (Sevova et al., 2010). Research has indicated 81 
TbSLS substrate specificity is dictated by natural variations in a small number of active site 82 
residues, thought to be involved in acid-base catalysis (Goren et al., 2011). Establishing the 83 
functions of the TbSLSs has clarified how the parasite is capable of altering its sphingolipid 84 
complement during its life cycle (Mina et al., 2009; Sevova et al., 2010), an observation 85 
further confirmed by recent sphingolipidomic analysis (Guan and Mäser, 2017). Currently, 86 
trypanosomatids are the only organisms known to synthesise sphingolipid species with 87 
choline, ethanolamine and inositol headgroups (Serricchio and Bütikofer, 2011; Guan and 88 
Mäser, 2017).  89 
In comparison to the knowledge of T. brucei sphingolipid biosynthesis that has already been 90 
acquired, little is known of the processes involved in the parasites’ sphingolipid catabolism. 91 
The catabolism of sphingolipids in eukaryotes takes place via the degradation pathway  92 
(Fig. 1B), predominantly in lysosomes and late endosomes, but also in other cellular 93 
locations (Kolter and Sandhoff, 1999; Jenkins et al., 2009). A number of different enzymes 94 
are involved in the degradative process (ceramidases, lyases, phospholipase D), but one 95 
major group of proteins responsible for sphingolipid turnover in mammalian cells is the 96 
sphingomyelinase (SMase) enzyme family (Kolter and Sandhoff, 1999). As indicated by their 97 
name, the primary substrate of these enzymes in mammals is SM, which is hydrolysed to 98 
yield ceramide and choline-phosphate (ChoP) (Jenkins et al., 2011). T. brucei has a single 99 
neutral SMase (TbnSMase) (Q57U95), a membrane protein with two identified 100 
transmembrane domains at its C-terminus (Young and Smith, 2010). TbnSMase has been 101 
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localised to the ER in bloodstream form parasites, and genetically confirmed as a potential 102 
drug target (Young and Smith, 2010). The activity of this protein is thought to be essential 103 
due to its intrinsic roles in vital biochemical processes, including choline and ceramide 104 
homeostasis, and endocytosis. This is particularly relevant to the coupling of endocytic and 105 
exocytic mechanisms with post-Golgi sorting of GPI-anchored variant surface glycoprotein 106 
(VSG), which is needed to maintain VSG surface density (Young and Smith, 2010). VSG 107 
molecules form the protective coat that permits T. brucei parasites to evade the host immune 108 
system (Mugnier et al., 2016). The importance of TbnSMase corroborates findings relating to 109 
the single leishmanial sphingolipid degradative enzyme (ISCL), another nSMase homologue 110 
(Zhang et al., 2009; McConville and Naderer, 2011). ISCL IPCase activity is required for  111 
L. major promastigote stationary phase survival, most noticeably at acidic pH (Xu et al., 112 
2011). The enzyme’s SMase function is necessary for amastigote proliferation and virulence 113 
in mammalian hosts (Zhang et al., 2009, 2012). This means that the importance of 114 
leishmanial ISCL activity is linked to cell cycle stage (Zhang et al., 2012). Similarly, 115 
inhibiting the nSMase/lyso-PC phospholipase C of Plasmodium falciparum disrupts parasite 116 
intra-erythrocytic proliferation, suggesting the protein could serve as a drug target (Hanada et 117 
al., 2002). In previous research, TbnSMase was shown to catabolise SM effectively, but was 118 
inactive towards phosphatidylcholine (PC) (Young and Smith, 2010). This initial analysis has 119 
now been taken forward to provide a more comprehensive overview of TbnSMase lipid 120 
degradative activity and specificity.  121 
MATERIALS AND METHODS 122 
Unless otherwise stated, all reagents and materials were purchased from Sigma, Promega,  123 
Thermo Scientific or VWR. C-1-P (d18:1/16:0), EPC (d17:1/12:0), SM (brain, porcine),  124 
dipalmitoyl-PC and dimyristoyl-PC (used as a mass spectrometry standard) were purchased 125 
from Avanti Polar Lipids. SM (D18:1/6:0), lyso-PC (from egg yolk), S-1-P (d18:1), and 126 
galactosylceramide were purchased from Sigma. EPC (from buttermilk, semi-synthetic) was 127 
purchased from Matreya LLC. Procyclic cell culture media were filter sterilised with either 128 
Millex GP 0.22 µM syringe filters or Triple Red 0.22 µM vacuum filtration units. Parasite 129 
cultures were maintained in Greiner Bio-One CELLSTAR® tissue culture flasks. 130 
  131 
  132 
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Recombinant expression of TbnSMase (Q57U95) in E. coli 133 
A pGEX-6P-1-TbnSMase expression construct was employed as previously described 134 
(Young and Smith, 2010). The expression construct was used to transform BL21 pLysSGold 135 
E. coli. Positive clones were selected using ampicillin-agar plates (100 µg mL
-1
) 136 
supplemented with chloramphenicol (34 µg mL
-1
). Three bacterial colonies were used to 137 
inoculate 3 x 10 mL of LB media (Miller composition, supplemented with 50 µg mL
-1
 138 
ampicillin and 34 µg mL
-1
 chloramphenicol). After a 24 hour incubation, the 10 mL 139 
overnight cultures were combined in a single tube (30 mL total volume). The combined 140 
culture was then used to inoculate 3 x 1 L auto-induction (AI) media (Formedium, 141 
supplemented with 50 µg mL
-1
 ampicillin and 34 µg mL
-1 
chloramphenicol), using 10 mL of 142 
overnight culture per litre flask of AI media. Cells were grown at 37°C for 4 hours before the 143 
temperature was decreased to 25°C for a further 20 -hour incubation.  144 
GST-TbnSMase-enriched bacterial membranes were prepared from these cultures. Pellets of 145 
500 mL spun-down culture were washed in PBS and stored at -80°C until they could be 146 
processed.  147 
TbnSMase-enriched bacterial membrane preparation 148 
The protocol described is adapted from methods previously outlined (Young and Smith, 149 
2010). Pellets of 500 ml spun-down bacterial culture were suspended and lysed in 10 mL 150 
lysis buffer (50 mM Tris.HCl (pH 8.0), 300 mM NaCl, 10% glycerol (v/v), 5 mM MgCl2,  151 
1 mM DTT), containing 0.2 mg mL
-1
 lysozyme (Sigma), Merck Millipore Benzonase® 152 
Endonuclease (250 units mL
-1
 lysate) and 1 x protease inhibitor tablet (Roche). The lysis 153 
solution was incubated for 30 minutes at 37°C, followed by probe sonication at 4°C  154 
(6 minutes total, 30 seconds on/30 seconds off). The lysate was then centrifuged at  155 
14,500 x g, 20 minutes. The product supernatant was divided amongst 3.2 mL capacity 156 
Beckman Coulter ultra-centrifuge tubes (x 3) for ultra-centrifugation at 100,000 x g, 1 hour. 157 
Pellets were washed with 1.5 mL PBS. Bacterial membrane pellets were then suspended in 158 
500 µL buffer each (100 mM Tris-HCl (pH 7.4), 10 mM MgCl2, 20% glycerol) using a 159 
combination of vortexing and water bath sonication (25°C, 4 minutes). The total membrane 160 
suspension (1500 µL total volume) was mixed in a single tube and was then aliquoted  161 
(50-100 µL). Aliquots were flash-frozen using liquid nitrogen and stored at -80°C. Total 162 
protein in each membrane preparation was quantified using the BCA Protein Assay Kit 163 
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(Thermo Scientific). The presence of TbnSMase in bacterial membranes was confirmed by 164 
mass spectrometry. 165 
Amplex® UltraRed assay 166 
Amplex® UltraRed assay coupling enzyme solutions were prepared from lyophilized 167 
powders using dH2O, and were stored as small aliquots at -20°C. Alkaline phosphatase  168 
(AlkPhos) (Sigma) from bovine intestinal mucosa was prepared as a 400 units mL
-1 
stock 169 
solution. Choline oxidase (ChoOx) (Sigma) from Alcaligenes sp. was prepared at  170 
20 units mL
-1
, horseradish peroxidase (HRP) (Sigma) at 200 units mL
-1
. Desiccated aliquots 171 
of Amplex® UltraRed reagent (Thermo Scientific) were suspended in 340 µL DMSO, as 172 
directed by the manufacturer, and stored at -20°C in small aliquots. To assay the aqueous 173 
fractions of biphasically separated GST-TbnSMase SM substrate reactions, aqueous phases 174 
were dried using a Savant SPD121P SpeedVac concentrator. The fractions were suspended in 175 
100 µL reaction buffer (100 mM HEPES (pH 7.4), 10 mM MgCl2) and divided between  176 
2 wells of a black 96-well reaction plate (50 µL per well). Additional reaction buffer (50 µL) 177 
was then added to each well. A mastermix of Amplex® assay components (coupling enzymes 178 
and Amplex® UltraRed reagent) was prepared. The mastermix accounted for the addition of 179 
2 µL AlkPhos, 1.5 µL ChoOx, 1 µL HRP, 0.25 µL Amplex UltraRed reagent and 95.25 µL 180 
reaction buffer per well (total reaction volume per well was 200 µL). Change in fluorescence 181 
(Ex. 560 nm, Em. 587 nm) was then monitored for 1 hour using a Spectra Max Gemini XPS 182 
fluorescence plate reader at 37°C. Results were recorded using SoftMax Pro v 5.2 software.  183 
Lipid substrate activity assays 184 
Lipid substrates were suspended in 2% Triton X-100 to the desired stock concentration 185 
through vortexing and water-bath sonication (10 minutes). Substrate mass was substrate- and 186 
analysis-dependent (20-50 nmoles), but each was added to reactions (50-100 µL total 187 
volume) to a final concentration of 0.1-0.2% Triton X-100. Substrates were incubated with 188 
TbnSMase-enriched bacterial membranes (~100 µg total protein) in 1.5 mL  189 
solvent-resistant microcentrifuge tubes. In heat-inactivated protein reactions, protein aliquots 190 
were heated to 95°C (20 minutes) prior to substrate addition. Reactions were performed in 191 
100 mM HEPES (pH 7.4), 10 mM MgCl2 buffer. On substrate addition, reactions were mixed 192 
briefly and sonicated for 30 seconds in a water bath (25°C). Reaction tubes were then 193 
incubated at 37°C (4 hours) in a water bath. Following incubation, reactions were quenched 194 
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with 800 µL CHCl3. If required, mass spectrometry standards (e.g. PC 28:0) were then added 195 
(500 pmoles), prior to the addition of 250 µL dH2O. The organic phase was isolated 196 
following the Bligh and Dyer biphasic separation method (Bligh and Dyer, 1959), and dried 197 
under nitrogen.  198 
Parasite lysate NBD-IPC activity assays 199 
Cells were suspended in lysis buffer (25 mM Tris (pH 7.5), 0.1% Triton X-100, 1 x protease 200 
inhibitor tablet (Roche)) to a density of ≥ 2 x 10
8
 cells mL
-1
, and were incubated on ice for  201 
5 minutes. Subsequently, 4 x 10
6
 parasites from each stock were transferred to each reaction. 202 
Parasites were incubated with 0.8 nmoles NBD-IPC, in 50 mM Tris (pH 7.5), 5 mM MgCl2,  203 
5 mM DTT, 0.1 % Triton X-100 reaction buffer, for 1 hour at 25 °C with gentle agitation 204 
(protected from the light). Following incubation, reactions were quenched with the addition 205 
of 1 mL CHCl3. Subsequently, 500 µL MeOH and 200 µL dH2O were quickly added. 206 
Samples were vortex mixed, then left to stand (protected from the light). The organic phase 207 
from each sample was isolated through biphasic separation, and dried under nitrogen. 208 
High-performance thin-layer chromatography 209 
HPTLC analysis of EPC and NBD-IPC substrate reactions was conducted using a  210 
CHCl3: MeOH: dH2O solvent system (65:25:4). Dried lipid samples were resuspended in 2:1  211 
CHCl3: MeOH (10-20 µL volume) and were gradually spotted onto HPTLC plates.  212 
EPC reaction results were visualised by treating HPTLC plates with ninhydrin solution  213 
(1% w/v in butan-1-ol). NBD-IPC reaction results were visualised via fluorescence imaging 214 
using a Typhoon FLA 7000 (GE), with CY2 (filter Y520, 473 nm laser) and Sypro Ruby 215 
(filter O580, 473 nm laser) settings. 216 
Procyclic form T. brucei lipid extract preparation 217 
T. brucei (Lister 427 (29-13) strain) procyclic (PCF) parasites were grown in SDM-79 media 218 
at pH 7.4, as previously described (Brun and Schönenberger, 1979). Drugs G418  219 
(15 µg mL
-1
) and hygromycin (50 µg mL
-1
) were included in the media in order to maintain 220 
the expression of a tetracycline repressor and T7 RNA polymerase (Wirtz et al., 1999). A  221 
10 ml culture of PCF cells (~1 x 10
7
 cells mL
-1
) was pelleted via centrifugation at 800 x g,  222 
10 minutes. The cell pellet was resuspended in a minimal volume of media (~ 500 µL) and 223 
transferred to a microcentrifuge tube for further centrifugation (3800 x g, 3 minutes). Cells 224 
Page 8 of 38
Cambridge University Press
Parasitology
For Peer Review
9 
 
were washed in 1 mL PBS, and then re-pelleted (3800 x g, 3 minutes). The pellet was 225 
resuspended in 200 µL PBS and transferred to a glass vial containing 750 µL 2:1 226 
MeOH:CHCl3 for biphasic separation, based on the method described by Bligh and Dyer 227 
(Bligh and Dyer, 1959). The sample was dried under nitrogen and stored at 4°C until use. 228 
Electrospray tandem mass spectrometry 229 
Lipid samples were analysed by electrospray tandem mass spectrometry (ESI-MS/MS) with 230 
an AB-Sciex Qtrap 4000 triple quadrupole mass spectrometer, incorporating an Advion 231 
TriVersa NanoMate nanoelectrospray ionisation source. Single-stage MS in negative ion 232 
mode was used to obtain survey scans of phosphatidylethanolamine (PE),  233 
ethanolamine-phosphoceramide (EPC), phosphatidylinositol (PI), inositol-phosphoceramide 234 
(IPC) and ceramide (Cer) species (cone voltage = 1.25 kV). Positive ion mode survey scans 235 
were used to detect phosphatidylcholine (PC) and sphingomyelin (SM) species  236 
(cone voltage = 1.25 kV). In tandem mass spectrometry, nitrogen was the collision gas. To 237 
examine PC/SM species, positive ion mode scans to detect precursors of m/z 184 were 238 
performed, with 50 eV collision energy (CE). In negative ion mode, precursors of m/z 196 239 
scans allowed the identification of PE and EPC lipids, precursors of m/z 241 scans were used 240 
to observe PI and IPC species (CE = 60). Spectra were acquired over or within the range of  241 
120-1000 m/z, and each spectrum represents a minimum of 30 consecutive scans. Samples 242 
were run using a 1:1 solvent mixture of 2:1 MeOH: CHCl3 and  243 
6:7:2 acetonitrile: isopropanol: dH2O. 244 
RESULTS 245 
GST-TbnSMase was recombinantly expressed in E. coli to produce TbnSMase-enriched 246 
bacterial membranes, using previously described methods (Young and Smith, 2010). The 247 
presence of the GST-TbnSMase membrane protein was confirmed using mass spectrometry 248 
(Fig. S1). After isolating the bacterial membranes via ultra-centrifugation, it was possible to 249 
assay GST-TbnSMase activity directly from the membranes with minimal bacteria-derived 250 
background activity, removing the need for protein purification. This had also been achieved 251 
during previous research into TbnSMase activity (Young and Smith, 2010). To confirm the 252 
GST-TbnSMase recombinant protein was active, GST-TbnSMase-enriched bacterial 253 
membranes were first incubated at 37 °C for 4 hours with a sphingomyelin (SM) substrate. 254 
The substrate used was Avanti Polar Lipids brain SM (product no. 860062). Although this 255 
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product is enriched for SM 36:1 (d18:1/18:0), as a natural lipid preparation the product is a 256 
mixture of brain SM species. The spectra presented here are consistent with the recently 257 
released Avanti Polar Lipids fatty acid distribution analysis for this product (Fig. S2) 258 
(Avanti Polar Lipids, 2018). Following SM substrate incubation, reactions were biphasically 259 
separated using 2:1 CHCl3: MeOH to isolate the lipid-rich organic phase. ESI-MS/MS was 260 
used to detect the levels of choline-containing (SM) lipid species in lipid samples derived 261 
from both active GST-TbnSMase and heat-inactivated GST-TbnSMase reactions (Fig. 2A 262 
and 2B, see also Fig. S3). A dimyristoyl-PC standard was added to each sample during lipid 263 
extraction, allowing SM substrate peak intensities to be normalised against the intensity of 264 
the internal standard. Relative peak intensities for each SM substrate species are shown  265 
(Fig. 2C). 266 
The catabolic activity of GST-TbnSMase towards sphingomyelin had been demonstrated 267 
previously (Young and Smith, 2010), here providing confirmation that the GST-TbnSMase 268 
recombinant protein was active. However, the use of ESI-MS/MS allowed the relative 269 
turnover of individual SM species present in the substrate mixture to be compared (Fig. 2C). 270 
The results indicate that GST-TbnSMase is active towards SM species with a range of  271 
fatty acid chain lengths (C16-C24). There was a 2.6-fold (62%) decrease in  272 
SM 42:1 (d18:1/24:0)/SM 42:2 (d18:1/24:1), compared to a 1.5-fold (35%) decrease in  273 
SM 36:1 (d18:1/18:0), despite the latter lipid being the prevalent species in the SM substrate 274 
mixture. This may indicate GST-TbnSMase preferentially degrades sphingolipid species of 275 
specific fatty acid chain lengths. SM substrate catabolism was further confirmed by 276 
identification of product ceramide chloride adducts [M + Cl]
-
 in negative ion mode survey 277 
scans (Fig. 3). Product ceramides were observed in the active GST-TbnSMase reaction  278 
(Fig. 3A), and were absent from the heat-inactivated control (Fig. 3B). Additionally, aqueous 279 
fractions isolated during biphasic separation of SM substrate reactions were tested for the 280 
presence of choline phosphate. The aqueous fractions were used as substrates for the 281 
Amplex® UltraRed assay system. In this assay (Fig. S4), the coupling enzyme alkaline 282 
phosphatase (AlkPhos) is included to dephosphorylate choline phosphate, yielding choline. 283 
The choline produced then serves as a substrate for the second coupling enzyme in the 284 
system: choline oxidase (ChoOx). Only the aqueous fractions from the active  285 
GST-TbnSMase reactions, in the presence of alkaline phosphatase, induced significantly 286 
increased rates of fluorescence change (Fig. 3C). These results confirm GST-TbnSMase is a 287 
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phosphodiesterase C enzyme, degrading SM substrates to form ceramide and choline 288 
phosphate. 289 
 290 
Having established the GST-TbnSMase protein was active, the enzyme’s activity towards a 291 
number of different sphingolipid substrates was examined. As already highlighted,  292 
T. brucei is known to produce SM, EPC and IPC. Thus, it was important to examine the 293 
activity of TbnSMase towards EPC and IPC sphingolipids. Firstly, GST-TbnSMase was 294 
incubated with an EPC substrate. The EPC substrate used was supplied by Mattreya LLC 295 
(product no. 1327), a semi-synthetic preparation derived from bovine buttermilk. No fatty 296 
acid distribution analysis is available for this product. However, the average molecular 297 
weight reported for the product (mw = 773) appears consistent with our analysis (Fig. 4A). 298 
Lipid extracts from the EPC substrate reactions were analysed in ESI-MS/MS negative ion 299 
mode survey scans. The EPC species present in the substrate (Fig. 4A) were efficiently 300 
degraded by GST-TbnSMase, yielding ceramide products (Fig. 4B). These products were 301 
absent from the heat-inactivated GST-TbnSMase control and the EPC/Triton X-100 detergent 302 
mixed micelles supplied to the reactions (Fig. 4C and 4D). Additionally, GST-TbnSMase 303 
degradative activity towards EPC was shown via HPTLC (Fig. S5). GST-TbnSMase was also 304 
incubated with a lipid substrate mixture containing equimolar concentrations of SM 305 
(d18:1/6:0, Avanti Polar Lipids product no.860582) and EPC (d17:1/12:0, Avanti Polar 306 
Lipids product no.860529).This competition assay indicated GST-TbnSMase lacks a 307 
sphingolipid substrate preference (Fig. S6). However, given the high levels of substrate 308 
turnover for both species, it is possible increasing the concentrations of both substrates may 309 
lead to a more marked preference for SM over EPC. Additionally, as EPC (d17:1/12:0) is the 310 
only pure EPC substrate commercially available, it is not possible to assess the impact of 311 
varying the sphingoid base and fatty acid composition on substrate turnover. 312 
 313 
Currently, pure IPC lipid species are only available commercially through custom synthesis.  314 
GST-TbnSMase was shown to catabolise a custom synthesised NBD-conjugated IPC 315 
substrate (Fig. S7). However, the synthetic nature of this IPC substrate makes it difficult to 316 
draw conclusions regarding the physiological relevance of this activity. It is well established 317 
that the prevalent sphingolipid in procyclic form T. brucei is IPC (Richmond et al., 2010). 318 
Therefore, a lipid extract from procyclic parasites was used to form a mixed micelle IPC 319 
substrate for GST-TbnSMase. Negative ion mode scans to detect inositol-containing lipids 320 
(precursors of m/z 241) were used to identify the IPC species present in the procyclic  321 
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T. brucei extract (Fig. 5A). Negative ion mode survey scans were then employed to search 322 
for ceramide chloride adducts [M + Cl]. Significant peaks corresponding to ceramide species 323 
were observed in the active GST-TbnSMase reaction (Fig. 5B), and were only observed at 324 
low levels in the heat-inactivated control (Fig. 5C, see also Fig. S8). Taken together, these 325 
results suggest GST-TbnSMase is also capable of catabolising natural IPC species to form 326 
ceramide and inositol-1-phosphate. 327 
 328 
The ability of GST-TbnSMase to degrade SM, EPC and IPC indicates the enzyme does not 329 
distinguish between its sphingolipid substrates based upon headgroup identity. To further 330 
explore this finding, GST-TbnSMase was incubated with a ceramide-1-phosphate 331 
(d18:1/16:0) substrate (Avanti Polar Lipids product no. 860533). A ceramide (d18:1/16:0) 332 
chloride adduct [M + Cl]
-
was apparent in the lipid extract from the active GST-TbnSMase 333 
reaction (Fig. 6A), and was absent from the control (Fig. 6B). This result suggests lipid  334 
headgroups are not involved in GST-TbnSMase substrate recognition. However,  335 
GST-TbnSMase does not appear to degrade glycosphingolipids, as no apparent catabolism 336 
was observed upon incubating GST-TbnSMase with a mixture of galactosylceramide 337 
substrate species (Sigma product no. C4905) (data not shown). This indicates that although 338 
GST-TbnSMase does not require a headgroup for lipid substrate turnover, features of the 339 
headgroup can impede substrate catabolism. It was also observed that the enzyme cannot 340 
degrade S-1-P (d18:1, Avanti Polar Lipids product no. 860492), as the level of the substrate 341 
species remained unchanged in lipid extracts from an active GST-TbnSMase reaction and 342 
controls (data not shown). This finding indicates ceramide is a crucial component of  343 
GST-TbnSMase sphingolipid substrates.  344 
 345 
Finally, GST-TbnSMase activity towards choline-containing phospholipids was reassessed. 346 
During previous research into TbnSMase, catabolic activity towards PC and lyso-PC lipid 347 
substrates could not be detected (Young and Smith, 2010). Re-assessing GST-TbnSMase 348 
activity towards PC (16:0/16:0) using ESI-MS/MS analysis failed to establish any substrate 349 
turnover (Avanti Polar Lipids product no. 850355) (data not shown). However, precursors of 350 
m/z 184 scans in positive ion mode revealed that GST-TbnSMase does turnover lyso-PC 351 
species (Fig. 7). There was a marked reduction in lyso-PCs (16:0) and (18:0) only in the 352 
presence of active GST-TbnSMase (Fig. 7A), relative to a PC (10:0/10:0) standard included 353 
in all lyso-PC reactions. This decrease did not occur in the control (Fig. 7B). Additionally, 354 
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the lyso-PC analogues miltefosine and edelfosine were previously shown to inhibit  355 
GST-TbnSMase (Young and Smith, 2010). This led to speculation that the previously 356 
observed inhibition of the enzyme’s activity by lyso-PC analogues may be due to these 357 
compounds acting as competing substrates. Testing miltefosine as a potential substrate for 358 
GST-TbnSMase (5-50 nmoles) in the Amplex® UltraRed assay system did not produce any 359 
data to suggest this lyso-PC analogue is turned over by GST-TbnSMase (data not shown). 360 
This indicates lyso-PC analogues are not competitive substrates for GST-TbnSMase. 361 
However, the possibility remains that these compounds may be tightly bound to the enzyme’s 362 
active site, preventing the ChoP release required for assay detection.  363 
DISCUSSION 364 
Sphingolipid metabolism in kinetoplastid parasites has long been established as a potential 365 
target for anti-parasitic drug development (Smith and Bütikofer, 2010; Mina and Denny, 366 
2017). However, research has focused almost exclusively on the pathways involved in 367 
sphingolipid biosynthesis. Initial research into the nSMase found in T. brucei showed this 368 
enzyme has sphingolipid catabolic activity (Young and Smith, 2010). TbnSMase is the only 369 
currently identified T. brucei protein that displays this function. Unusually, the parasites 370 
appear to lack phospholipase D activity, which generally facilitates eukaryotic SM and PC 371 
catabolism. The substrate specificity of TbnSMase was examined to improve understanding 372 
of T. brucei sphingolipid catabolism and salvage. 373 
 374 
TbnSMase is now known to turnover SM, EPC and IPC sphingolipid species. This is 375 
consistent with the established sphingolipid composition of T. brucei (Richmond et al., 2010; 376 
Guan and Mäser, 2017): IPC predominates in procyclic parasites, whilst almost equal 377 
proportions of SM and EPC species are found in the bloodstream form  378 
(Guan and Mäser, 2017). In light of this knowledge, it may seem unsurprising that TbnSMase 379 
is active towards all three of these sphingolipid classes, only distinguished structurally by 380 
their headgroup (choline, ethanolamine and inositol). However, to our knowledge, this 381 
breadth of sphingolipid substrate specificity has not been documented previously for a lipid 382 
catabolic enzyme. It is possible that other sphingolipid degradative enzymes (especially those 383 
found in other kinetoplastids) share this ability but have not been tested. If this wide-ranging 384 
substrate specificity is not found in mammalian nSMase homologues, it may be possible to 385 
exploit these differences to create TbnSMase-specific substrate analogue inhibitors. The 386 
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TbnSMase activity reported here precludes the need for other sphingolipid degradative 387 
enzymes in the ER and rationalises the constitutive expression of this enzyme in both 388 
procyclic and bloodstream forms. However, no activity towards glycosphingolipids was 389 
observed, indicating phosphate groups may be an obligatory feature of TbnSMase substrates. 390 
It has been reported that T. brucei possess trace levels of glycosphingolipids, 391 
glucosylceramide species having been identified in several studies (Uemura et al., 2006; 392 
Fridberg et al., 2008; Richmond et al., 2010). These could be endocytosed host 393 
glycosphingolipids, as no glycosphingolipid biosynthetic enzymes have been formally 394 
identified in T. brucei (Uemura et al., 2006; Richmond et al., 2010; Guan and Mäser, 2017). 395 
Only galactosylceramide species were tested as possible substrates for TbnSMase, thus it 396 
remains possible the enzyme is active towards other glycosphingolipids. Alternatively, 397 
another (other) unidentified enzyme(s) may be responsible for T. brucei glycosphingolipid 398 
catabolism, possibly within the lysosome. 399 
 400 
ESI-MS/MS analysis indicates that TbnSMase preferentially catabolises SM species with 401 
specific fatty acid chain lengths. A mor  significant decrease in SM 42:1 (d18:1/24:0)/ 402 
SM 42:2 (d18:1/24:1) occurred relative to SM 36:1 (d18:1/18:0), despite the latter species 403 
being more prevalent in the substrate mixture. This suggests that TbnSMase activity may be 404 
geared towards recycling specific long-chain fatty acids, which can then be utilised in other 405 
biosynthetic processes. Defining a crystal structure for TbnSMase may reinforce these 406 
preliminary observations, particularly if the structure provides insight into substrate binding 407 
and potential regulation. Few crystal structures for nSMase proteins are currently available, 408 
and most studies have focused on the binding of choline phosphate to the active site 409 
(Openshaw et al., 2005; Ago et al., 2006). However, TbnSMase does not seem to distinguish 410 
between its substrates based on headgroup identity, instead appearing to preferentially 411 
degrade substrates with specific fatty acids. This finding indicates that the fatty acid 412 
composition of lipid substrates may be of greater interest when considering enzyme-substrate 413 
interactions. In support of this view, TbnSMase was shown to actively degrade  414 
ceramide-1-phosphate, which lacks a polar alcohol headgroup entirely. However, the enzyme 415 
was unable to catabolise sphingosine-1-phosphate, indicating the presence of an amide bound 416 
fatty acid at the sn-2 position is vital for sphingolipid substrate recognition. Indeed, in the 417 
case of TbnSMase, the critical aspect of lipid substrate recognition appears to centre on the 418 
binding of the phosphate and fatty acid moieties to sphingosine or glycerol backbones. 419 
TbnSMase is now known to degrade lyso-PC in addition to sphingolipids. This aspect of 420 
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TbnSMase activity brings the enzyme in line with the nSMase found in Plasmodium 421 
falciparum parasites (PfnSMase) (Hanada et al., 2002). Both PfnSMase and TbnSMase are 422 
inactive towards PC substrates, despite their ability to degrade lyso-PCs. This points to the 423 
diacylglycerol moiety of phospholipids impairing substrate binding to these SMase enzymes, 424 
and that removal of the fatty acid at the sn-2 position alleviates this inhibition. Thus, the 425 
requirements for glycerophospholipid recognition are the inverse of sphingophospholipid 426 
recognition.  427 
 428 
TbnSMase is the first identified T. brucei enzyme shown to be capable of degrading  429 
lyso-PCs, which are believed to be a primary source of parasite choline during bloodstream 430 
infection (Bowes et al., 1993; Smith and Bütikofer, 2010; Macêdo et al., 2013). This is due to 431 
the parasites lacking a choline de novo biosynthesis pathway (Smith and Bütikofer, 2010), 432 
and lyso-PC concentration in the blood being 10-fold greater than choline (Macêdo et al., 433 
2013). Mammalian bloodstream T. brucei require an abundant source of choline, as over 50% 434 
of their lipid complement consists of choline-containing lipids (Smith and Bütikofer, 2010). 435 
The T. brucei phospholipase A1 was shown to degrade PC, but not lyso-PC species 436 
(Richmond and Smith, 2007a; b). A plasma membrane phospholipase that degrades lyso-PC 437 
has been postulated (Bowes et al., 1993) but has yet to be identified. This activity in 438 
TbnSMase indicates the enzyme may be responsible for lyso-PC turnover in the ER. Research 439 
into the essentiality of TbnSMase showed that compromised enzyme function led to a 440 
concomitant decrease in the parasite’s rate of endocytosis (Young and Smith, 2010). This 441 
could have wide-ranging effects on the parasites, but was thought to have particularly 442 
impacted T. brucei choline homeostasis due to the parasites’ dependence upon endocytosed 443 
and recycled choline-containing lipids. This impact was indicated by a marked decrease in 444 
phosphatidylcholine (PC) and increased intracellular diacylglycerol (DAG), suggesting  445 
PC de novo biosynthesis via the Kennedy pathway had been disrupted (Young and Smith, 446 
2010). The newly discovered ability of TbnSMase to degrade lyso-PC and SM species aligns 447 
with these observations, indicating decreased enzyme activity has a direct impact on choline 448 
homeostasis. This underlines the importance of TbnSMase function in sustaining the 449 
intracellular choline metabolite levels required for parasite survival and propagation.  450 
 451 
Further research is required to identify and characterise other enzymes that underpin lipid 452 
catabolism and salvage in these kinetoplastid parasites, which represent a valuable model 453 
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system for eukaryotic lipid metabolism (Serricchio and Bütikofer, 2011). As in the case of 454 
TbnSMase, the activity of these enzymes may prove vital, opening new areas of T. brucei 455 
biochemistry to drug development.  456 
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 600 
FIGURE LEGENDS 601 
Fig. 1: Trypanosoma brucei sphingolipid metabolism. A) The currently proposed pathway for T. brucei  602 
de novo sphingolipid biosynthesis is shown. SPT-serine-palmitoyltransferase (Q580D0);  603 
3-KSR – 3-ketosphinganine reductase (Q38BJ6); CerS – ceramide synthase (Q57V92, Q583F9);  604 
DES – dihydroceramide desaturase (Q583N4); TbSLSs 1-4 – T. brucei sphingolipid synthases 1-4 (Q38E53; 605 
Q38E54; Q38E55; Q38E56). Biosynthesis of ceramide (36:1) has been used here as an example.  606 
B) A simplified overview of eukaryotic sphingolipid degradation is provided (omitting glycosphingolipid 607 
catabolic pathways). A representative sphingolipid species (sphingomyelin (36:1)) is degraded in a step-wise 608 
process involving sphingomyelinases (SMases) and ceramidases (CDases). Lipid headgroups, such as choline 609 
phosphate, and sphingosine can be recycled to participate in de novo biosynthesis via the salvage pathway 610 
(green dashed arrows). Products ceramide and sphingosine can also be phosphorylated to produce signalling 611 
molecules ceramide-1-phosphate and sphingosine-1-phosphate respectively. ATP – adenosine triphosphate; 612 
ADP – adenosine diphosphate; CERK – ceramide kinase; SphK – sphingosine kinase.  613 
Fig. 2: ESI-MS/MS analysis of sphingomyelin substrate reactions. Spectra are ESI-MS/MS precursor ion 614 
scans to detect choline-containing lipids (precurors of m/z 184) in positive ion mode.  615 
A) GST-TbnSMase-enriched bacterial membranes plus SM substrate. B) heat-inactivated GST-TbnSMase 616 
enriched bacterial membranes plus SM substrate. (†) Highlights the dimyristoyl-PC (28:0) standard  617 
(500 pmoles). C) Peak intensities (cps), normalised against the intensity of the dimyristoyl-PC (28:0) standard, 618 
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for each significant sphingomyelin (SM) substrate lipid species are depicted. Values are mean intensities for 619 
triplicate reactions (n = 3).Error bars represent the standard error of each mean (±).  620 
Fig. 3: GST-TbnSMase catabolism of sphingomyelin yields ceramide and choline phosphate. Spectra are 621 
ESI-MS/MS survey scans in negative ion mode. A) GST-TbnSMase-enriched bacterial membranes plus SM 622 
substrate. B) heat-inactivated TbnSMase-enriched bacterial membranes plus SM substrate. Annotated ceramides 623 
have formed chloride adducts [M + Cl]-. (*) Highlights previously identified significant contaminants of 624 
negative ion mode surveys thought to be associated with the detergent. C) Aqueous fractions of sphingomyelin 625 
substrate reactions were used as substrates for the Amplex® UltraRed assay system, plus (+) or minus (-) the 626 
coupling-enzyme alkaline phosphatase (AlkPhos). Change in fluorescence (millirelative-fluorescence units per 627 
minute (mrfu min
-1
)) was monitored spectrophotometrically. Values represent average rate of fluorescence 628 
change for aqueous fractions derived from triplicate reactions (n = 3). Error bars represent the standard error of  629 
each mean (±).  630 
Fig. 4: ESI-MS/MS analysis of ethanolamine-phosphoceramide substrate reactions. Spectra are  631 
ESI-MS/MS survey scans in negative ion mode. A) EPC only (minus Triton X-100 detergent).  632 
B) GST-TbnSMase-enriched bacterial membranes plus EPC substrate. Annotated ceramides have formed 633 
chloride adducts [M + Cl]-. C) heat-inactivated GST-TbnSMase-enriched bacterial membranes plus EPC 634 
substrate. D) EPC/ Triton X-100 detergent mixed micelle substrate only. (*) Highlights previously identified 635 
significant contaminants of negative ion mode surveys thought to be associated with the detergent. 636 
Fig. 5: ESI-MS/MS analysis of T. brucei procyclic-extract (inositol-phosphoceramide) substrate reactions.  637 
A) ESI-MS/MS precursor ion scan of the procyclic lipid extract (IPC substrate) to detect inositol-containing 638 
lipids (precursors of m/z 241), in negative ion mode. The extract contains dihydroxylated ceramides, as well as 639 
trihydroxylated ceramides, the later denoted as‘t-’. B) ESI-MS/MS negative ion mode survey scans were used to 640 
detect ceramides in GST-TbnSMase and C) heat-inactivated GST-TbnSMase-enriched bacterial membranes 641 
plus IPC substrate reactions. Annotated ceramides have formed chloride adducts [M + Cl]-. 642 
Fig. 6: GST-TbnSMase catabolism of ceramide-1-phosphate yields ceramide. Spectra are ESI-MS/MS 643 
survey scans in negative ion mode. A) GST-TbnSMase-enriched bacterial membranes plus  644 
ceramide-1-phosphate (C-1-P) substrate. B) Non-TbnSMase-expressing bacterial membranes plus  645 
ceramide-1-phosphate substrate. The annotated ceramide (Cer) product species has formed a  646 
chloride adduct [M + Cl]
-
. 647 
Fig. 7: ESI-MS/MS analysis of lyso-PC substrate reactions. Spectra are ESI-MS/MS precursor ion scans to 648 
detect choline-containing lipids (precursors of m/z 184) in positive ion mode. A) GST-TbnSMase-enriched 649 
bacterial membranes with lyso-PC substrate. B) non-TbnSMase-expressing bacterial membranes with lyso-PC 650 
substrate. (†) Highlights the didecanoyl-PC (20:0) standard (500 pmoles). (*) Highlights previously identified 651 
significant contaminants of positive ion mode scans thought to be associated with the detergent. 652 
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Fig. S1: Presence of GST-TbnSMase in bacterial membranes was confirmed by mass spectrometry 
analysis. pLysSGold E. coli membrane fractions were separated via SDS-PAGE and stained with Coomassie. 
Fractions were run in duplicate (lanes 1-4 and again, in lanes 5-8). ‘-’ indicates the non-TbnSMase-expressing 
control bacterial membranes. ‘+’ signifies membrane fractions were derived from E. coli expressing  
GST-TbnSMase. The band thought to correspond to GST-TbnSMas  (annotated, lane 2) was excised 
(annotated, lane 6) and submitted for mass spectrometry analysis, which confirmed its identity as  
GST-TbnSMase.  
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Fig S2: Avanti fatty acid analysis of brain SM product 860062. This product 
(https://avantilipids.com/product/860062) was used as an SM substrate for GST-TbnSMase (see Fig. 2 and  
Fig. S3). Average fatty acid distribution for SM (d18:1/y) lipid species within the product are shown. 
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Fig. S3: Additional supporting spectra for GST-TbnSMase catabolism of sphingomyelin. Spectra are  
ESI-MS/MS precursor ion scans to detect choline-containing lipids (precursors of m/z 184) in positive ion 
mode. A) SM/Triton X-100 mixed micelle substrate only. B) Non-TbnSMase-expressing bacterial membranes 
plus SM substrate. (†) Highlights the dimyristoyl-PC (28:0) standard (500 pmoles).  
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Fig. S4: Amplex® Red assay system. Sphingomyelinase (SMase) activity results in sphingomyelin 
substrate catabolism, producing ceramide and choline-phosphate (ChoP). ChoP is then hydrolysed by the assay 
coupling enzyme alkaline phosphatase (AlkPhos), forming choline (Cho). Choline oxidase (ChoOx) oxidises 
choline to yield betaine and hydrogen peroxide (H2O2). As the ChoOx used in the assay is isolated from 
Alcaligenes sp., Cho is fully oxidised to betaine, via a betaine-aldehyde intermediate (not shown), and 2 moles 
of hydrogen peroxide (H2O2) are produced for every mole of Cho. The H2O2 is the oxidising agent for 
horseradish peroxidase (HRP) that catalyses the conversion of Amplex® Red to red-fluorescent resorufin.  
The rate of this conversion can be monitored spectrophotometrically (Ex. 560 nm, Em. 587 nm). For the work 
described here, Amplex® UltraRed, an optimised version of Amplex® Red, was used. However, no chemical 
structure or formula is available for Amplex® UltraRed and its red-fluorescent conversion product. 
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Fig. S5: HPTLC analysis of ethanolamine-phosphoceramide substrate reactions.  
1) EPC stock solution (no Triton X-100 detergent); 2) EPC/Triton X-100 detergent mixed micelle substrate in 
reaction buffer; 3) GST-TbnSMase-enriched bacterial membranes plus EPC substrate;  
4) non-TbnSMase-expressing bacterial membranes plus EPC substrate; 5) heat-inactivated  
GST-TbnSMase-enriched bacterial membranes plus EPC substrate; 6) heat-inactivated non-TbnSMase-
expressing bacterial membranes plus EPC substrate. 
  
 
Fig. S6: Sphingomyelin and ethanolamine-phosphoceramide substrate competition assay. A substrate 
mixture, containing equimolar concentrations (25 nmoles) of sphingomyelin and  
ethanolamine-phosphoceramide, was incubated with GST-TbnSMase. The percentage decreases (%) in the level 
of each substrate, relative to a TbnSMase negative control, are shown. 
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Fig. S7: HPTLC analysis of NBD-IPC substrate reactions. 1) bloodstream form T. brucei lysate with  
NBD-IPC substrate; 2) stumpy form T. brucei lysate with NBD-IPC substrate; 3) procyclic form T. brucei lysate 
with NBD-IPC substrate (stored prior to use); 4) NBD-IPC substrate only; 5) GST-TbnSMase-expressing E. coli 
lysate with NBD-IPC substrate; 6) non-GST-TbnSMase-expressing E. coli lysate with NBD-IPC substrate;  
7) procyclic form T. brucei lysate with NBD-IPC substrate (freshly prepared); 8) promastigote form  
L. major lysate with NBD-IPC substrate; 9) epimastigote form T. cruzi lysate with NBD-IPC substrate. 
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Fig. S8: Additional supporting spectra for T. brucei procyclic-extract (inositol-phosphoceramide) 
reactions. ESI-MS/MS precursor ion scans to detect inositol-containing lipids (precursors of m/z 241) in 
negative ion mode. A) GST-TbnSMase-enriched bacterial membranes plus procyclic extract (IPC) substrate.  
B) heat-inactivated GST-TbnSMase-enriched bacterial membranes plus IPC substrate. The substrate contains 
dihydroxylated ceramides, as well as trihydroxylated ceramides, the later denoted as‘t-’.C) ESI-MS/MS survey 
scan, in negative ion mode, of the IPC/Triton X-100 detergent mixed micelle substrate only. 
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